Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access

Core Insights - Just - Evotec Biologics has received a grant from the Gates Foundation to enhance global access to biotherapeutics through its molecular design suite, J.MD™ [1] - The investment will support ten new projects focused on optimizing monoclonal antibodies (mAbs) over the next three years, targeting improvements in titer, pharmacokinetics, immunogenicity, and stability [1] - The initiative aims to reduce the cost of goods for mAbs, making them more affordable and accessible, particularly in low- and middle-income countries to combat infectious diseases [1] Investment and Development - The grant continues the support for selected Gates Foundation grantees, emphasizing the importance of developing cost-effective biotherapeutics [1] - The focus on molecular optimization is expected to enhance the developability of mAbs, which is crucial for their widespread use [1] - The collaboration with the Gates Foundation highlights the commitment to addressing global health challenges through innovative biotechnological solutions [1]